RNS Number : 5711B
Source BioScience PLC
17 June 2016
FORM 8 (OPD)
PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER
Rules 8.1 and 8.2 of the Takeover Code (the "Code")
1. KEY INFORMATION
|
(a) Full name of discloser:
|
Source BioScience plc
|
|
(b) Owner or controller of interests and short positions disclosed, if different from
1(a):
The naming of nominee or vehicle companies is insufficient.
For a trust, the trustee(s), settlor and beneficiaries must be named.
|
N/A
|
|
(c) Name of offeror/offeree in relation to whose relevant securities this form
relates:
Use a separate form for each offeror/offeree
|
Source BioScience plc
|
|
(d) Is the discloser the offeror or the offeree?
|
Offeree
|
|
(e) Date position held:
The latest practicable date prior
to the disclosure
|
16 June 2017
|
|
(f) In addition to the company in 1(c) above, is the discloser making disclosures in
respect of any other party to the offer?
If it is a cash offer or possible
cash offer, state "N/A"
|
N/A
|
2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE
DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant
securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant
security.
(a) Interests and short positions in the relevant
securities of the offeror or offeree to which the disclosure relates
|
Class of relevant security:
|
|
|
|
Interests
|
Short positions
|
|
Number
|
%
|
Number
|
%
|
|
(1) Relevant securities owned and/or controlled:
|
Nil
|
-
|
Nil
|
-
|
|
(2) Cash-settled derivatives:
|
Nil
|
-
|
Nil
|
-
|
|
(3) Stock-settled derivatives (including options) and agreements to
purchase/sell:
|
Nil
|
-
|
Nil
|
-
|
|
TOTAL:
|
Nil
|
-
|
Nil
|
-
|
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements
to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
Details of any securities borrowing and lending positions or financial collateral arrangements
should be disclosed on a Supplemental Form 8 (SBL).
(b) Rights to subscribe for new securities
|
Class of relevant security in relation to which subscription right exists:
|
None
|
|
Details, including nature of the rights concerned and relevant percentages:
|
None
|
3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE
PARTY TO THE OFFER MAKING THE DISCLOSURE
|
Details of any interests, short positions and rights to subscribe (including directors'
and other employee options) of any person acting in concert with the party to the offer making the disclosure:
|
|
3(a) Beneficial holdings of the Directors of Source BioScience plc in its Ordinary
Shares
|
Director
|
Number of Ordinary Shares
|
Percentage of total issued share capital (%)
|
|
Laurie Turnbull
|
2,750,000
|
0.79
|
|
Dr Nick Ash
|
500,000
|
0.14
|
|
Dr Nick Leaves
|
1,028,557
|
0.29
|
3(b) Interests of the Directors in Source BioScience plc Ordinary Shares under the Source
BioScience Executive Share Option Scheme and the Source BioScience 2015 Long Term Incentive Plan
|
Director
|
Maximum number of Ordinary Shares awarded
|
Date of Grant
|
First exercisable date
|
Last exercisable date
|
Option price (pence)
|
|
Laurie Turnbull
|
500,000
|
31 Mar 2008
|
31 Mar 2011
|
30 mar 2018
|
7.88p
|
|
|
400,000
|
26 Apr 2010
|
26 Apr 2013
|
25 Apr 2020
|
8.25p
|
|
Dr Nick Ash
|
500,000
|
31 Mar 2008
|
31 Mar 2011
|
30 Mar 2018
|
7.88p
|
|
|
400,000
|
31 Mar 2009
|
31 Mar 2012
|
30 Mar 2019
|
4.63p
|
|
|
400,000
|
26 Apr 2010
|
26 Apr 2013
|
25 Apr 2020
|
8.25p
|
|
|
600,000
|
27 Sep 2013
|
27 Sep 2016
|
26 Sep 2023
|
9.38p
|
|
|
1,500,000
|
21 Oct 2013
|
21 Oct 2016
|
20 Oct 2023
|
9.50p
|
|
|
1,500,000
|
21 Oct 2013
|
21 Oct 2016
|
20 Oct 2023
|
9.50p
|
|
|
500,000
|
21 Oct 2013
|
21 Oct 2017
|
20 Oct 2024
|
9.50p
|
|
|
3,821,538
|
25 Jun 2015
|
15 Mar 2019
|
25 Jun 2025
|
nil
|
|
Dr Nick Leaves
|
200,000
|
31 Mar 2008
|
31 Mar 2011
|
30 Mar 2018
|
7.88p
|
|
|
300,000
|
31 Mar 2009
|
31 Mar 2012
|
30 Mar 2019
|
4.63p
|
|
|
300,000
|
26 Apr 2010
|
26 Apr 2013
|
25 Apr 2020
|
8.25p
|
|
|
300,000
|
24 Apr 2011
|
24 Apr 2014
|
23 Apr 2021
|
6.25p
|
|
|
400,000
|
27 Sep 2013
|
27 Sep 2016
|
26 Sep 2023
|
9.38p
|
|
|
1,000,000
|
21 Oct 2013
|
21 Oct 2016
|
20 Oct 2023
|
9.50p
|
|
|
1,600,000
|
21 Oct 2013
|
21 Oct 2016
|
20 Oct 2023
|
9.50p
|
|
|
400,000
|
21 Oct 2013
|
21 Oct 2017
|
20 Oct 2024
|
9.50p
|
|
|
3,108,462
|
25 Jun 2015
|
15 Mar 2019
|
25 Jun 2025
|
nil
|
|
Tim Metcalfe
|
2,769,231
|
25 Jun 2015
|
15 Mar 2019
|
25 Jun 2025
|
nil
|
|
Details of any open stock-settled derivative positions (including traded options), or agreements
to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
Details of any securities borrowing and lending positions or financial collateral arrangements
should be disclosed on a Supplemental Form 8 (SBL).
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
|
Details of any indemnity or option arrangement, or any agreement or understanding, formal
or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by
the party to the offer making the disclosure or any person acting in concert with it:
Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state "none"
|
|
None
|
(b) Agreements, arrangements or understandings relating
to options or derivatives
|
Details of any agreement, arrangement or understanding, formal or informal, between the
party to the offer making the disclosure, or any person acting in concert with it, and any other person relating
to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to
which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
|
|
None
|
(c) Attachments
Are any Supplemental Forms attached?
|
Supplemental Form 8 (Open Positions)
|
NO
|
|
Supplemental Form 8 (SBL)
|
NO
|
Date of disclosure:
|
17 June 2016
|
Contact name:
|
Dr Nick Ash
|
Telephone number:
|
+44 (0)115 973 9010
|
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and
must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market
Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638
0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
FEEUBVRRNKANAAR